12 Jan. 2021

BioVersys reports first dosing of BVL-GSK098 in clinical Phase I

BioVersys is proud to announce together with its partner GSK the first dosing of our Tuberculosis asset BVL-GSK098 in clinical Phase I. This is a grea...


18 Nov. 2020

BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of BV100

Today marks the start of the World Antimicrobial Awareness Week 2020 by the WHO, underlining once more the incredibly important health emergency that...


01 Sep. 2020

BioVersys Announces CHF 19 Million Financing to Advance Novel AMR Candidates into Clinical Development

BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious disease candid...


14 Juli 2020

BioVersys and Partners from Lille Sign Long-term Collaboration Agreement Creating a Unique Cross-Border AMR Cluster in Antimicrobial Research Excellence

BioVersys and partners, the Institut Pasteur de Lille and the University of Lille, from Région Hauts-de-France, sign a long-term collaboration agreeme...